CA2612021A1 - Compositions and methods for treating and diagnosing cancer - Google Patents

Compositions and methods for treating and diagnosing cancer Download PDF

Info

Publication number
CA2612021A1
CA2612021A1 CA002612021A CA2612021A CA2612021A1 CA 2612021 A1 CA2612021 A1 CA 2612021A1 CA 002612021 A CA002612021 A CA 002612021A CA 2612021 A CA2612021 A CA 2612021A CA 2612021 A1 CA2612021 A1 CA 2612021A1
Authority
CA
Canada
Prior art keywords
solid tumor
stem cells
cells
levels
tumor stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002612021A
Other languages
English (en)
French (fr)
Inventor
Xinhao Wang
John A. Lewicki
Austin L. Gurney
Michael F. Clarke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of Michigan System
Oncomed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, Oncomed Pharmaceuticals Inc filed Critical University of Michigan System
Publication of CA2612021A1 publication Critical patent/CA2612021A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002612021A 2005-06-13 2006-06-13 Compositions and methods for treating and diagnosing cancer Abandoned CA2612021A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69000105P 2005-06-13 2005-06-13
US60/690,001 2005-06-13
PCT/US2006/022934 WO2006138275A2 (en) 2005-06-13 2006-06-13 Compositions and methods for treating and diagnosing cancer

Publications (1)

Publication Number Publication Date
CA2612021A1 true CA2612021A1 (en) 2006-12-28

Family

ID=37571044

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002612021A Abandoned CA2612021A1 (en) 2005-06-13 2006-06-13 Compositions and methods for treating and diagnosing cancer

Country Status (6)

Country Link
US (3) US20070105133A1 (https=)
EP (1) EP1907858A4 (https=)
JP (1) JP2008546387A (https=)
AU (1) AU2006259583A1 (https=)
CA (1) CA2612021A1 (https=)
WO (1) WO2006138275A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
CN109837342A (zh) * 2017-11-28 2019-06-04 立森印迹诊断技术（无锡）有限公司 一种用于检测乳腺肿瘤良恶性程度的分级模型及其应用
CN113633778A (zh) * 2021-10-18 2021-11-12 广州医科大学附属肿瘤医院 Bex2在制备热化疗耐药胃癌增敏药物或制备预测疗效产品的应用
CN114940714A (zh) * 2022-05-20 2022-08-26 湖南师范大学 肝癌标志物soat1单克隆抗体制备及其应用

Families Citing this family (276)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290028B1 (en) 2000-06-05 2009-12-23 The Brigham And Women's Hospital, Inc. A GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7p15-21 AND USES THEREOF
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) * 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8008012B2 (en) * 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
ES2374311T3 (es) * 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
HUE050365T2 (hu) 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
US20130122504A1 (en) * 2011-11-14 2013-05-16 Lars Dyrskjot Andersen Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer
ES2636470T3 (es) 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
WO2006044017A2 (en) * 2004-08-13 2006-04-27 Jaguar Bioscience Inc. Systems and methods for identifying diagnostic indicators
WO2008125791A1 (en) * 2007-04-12 2008-10-23 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Cancer markers
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
US8747867B2 (en) 2004-09-30 2014-06-10 Ifom Fondazione Instituto Firc Di Oncologia Molecolare Cancer markers
JP2008524221A (ja) * 2004-12-17 2008-07-10 バイオノボ・インコーポレーテッド Ｅｐｉｍｅｄｉｕｍ属植物の抽出液を用いた方法
US7482029B2 (en) * 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
CA2628255C (en) * 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070220621A1 (en) * 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
NZ593226A (en) * 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
US20100278821A1 (en) * 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2007109347A2 (en) * 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and ly6 e: targets for cancer diagnosis and therapy
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US8535677B2 (en) 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2041574B1 (en) 2006-07-14 2016-11-16 The Regents of The University of California Cancer biomarkers and methods of use threof
EP2069793B9 (en) * 2006-08-29 2017-08-16 Oxford BioTherapeutics Ltd Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
WO2008036419A2 (en) * 2006-09-22 2008-03-27 The Regents Of The University Of Michigan Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
AU2008210421B2 (en) * 2007-01-30 2014-03-13 Pharmacyclics Llc Methods for determining cancer resistance to histone deacetylase inhibitors
US20110178154A1 (en) * 2007-02-06 2011-07-21 Birrer Michael J gene expression profile that predicts ovarian cancer subject response to chemotherapy
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
GB0706658D0 (en) * 2007-04-05 2007-05-16 Imp Innovations Ltd Breast cancer methods, medicaments and agents
DK2155248T3 (en) 2007-04-12 2015-09-14 Brigham & Womens Hospital Targeting abcb5 for cancer therapy
WO2008143795A1 (en) * 2007-05-11 2008-11-27 Champions Biotechnology, Inc. Human mesenchymal chrondrosarcoma xenograft model and its use in chemosensitivity testing
US20100183514A1 (en) * 2007-05-29 2010-07-22 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
CA2688477C (en) * 2007-06-01 2020-12-22 The Regents Of The University Of California Multigene prognostic assay for lung cancer
US20100303813A1 (en) * 2007-06-08 2010-12-02 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
WO2009009739A2 (en) * 2007-07-12 2009-01-15 Theracrine, Inc. Methods and compositions for facilitating cell death of cancer stem cells and for treating cancer
WO2009011911A2 (en) * 2007-07-18 2009-01-22 The Johns Hopkins University Methods of detecting prostate cancer
US8679759B2 (en) * 2007-08-01 2014-03-25 The Johns Hopkins University Esophageal cancer markers
WO2009021196A1 (en) * 2007-08-08 2009-02-12 Bionovo, Inc. Extracts of ligustrum lucidum and uses thereof
WO2009033025A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of asparagus conchinchinensis (lour.) merr of the liliaceae family and uses thereof
JP2010539085A (ja) * 2007-09-07 2010-12-16 バイオノボ・インコーポレーテッド マメ科ファミリーのキバナオウギのエストロゲン性抽出物およびその使用
US9155770B2 (en) * 2007-09-07 2015-10-13 Bionovo, Inc. Estrogenic extracts of Scuttelaria barbata D. don of the labiatae family and uses thereof
JP2010539086A (ja) * 2007-09-07 2010-12-16 バイオノボ・インコーポレーテッド マメ科ファミリーのクズのエストロゲン性抽出物およびその使用
EP2203743A4 (en) * 2007-09-20 2011-03-02 Univ Louisville Res Found PEPTIDE BIOMARKER FOR PREDICTING WEARNING OF THE KIDNEY FUNCTION AND A CHILDNESS
WO2009046118A1 (en) * 2007-10-01 2009-04-09 The Children's Hospital Of Philadelphia Cancer susceptibility loci located at chromosome 6p22 and chromosome 20 for use in diagnostic and therapeutic methods
EP2781223B1 (en) 2007-10-19 2017-02-22 Rappaport Family Institute for Research in the Medical Sciences Compositions comprising semaphorins for use in the treatment of cancer
US9808506B2 (en) 2007-10-19 2017-11-07 Rappaport Family Institute For Research In The Medical Sciences Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof
WO2009148470A1 (en) * 2007-10-25 2009-12-10 The Board Of Trustees Of Southern Illinois University Methods for diagnosing bowel disease
WO2009062104A2 (en) * 2007-11-09 2009-05-14 Baylor College Of Medicine Aberrant expression of zinc transporter zip4 (slc39a4) significantly contributes to human pancreatic cancer pathogenesis and progression
EP2219659A4 (en) * 2007-11-19 2010-11-17 Bionovo Inc METHODS OF DETECTION AND TREATMENT OF CANCERS USING BARBATA SCUTTELARIA EXTRACT
CA2706330A1 (en) * 2007-11-19 2009-06-04 Bionovo, Inc. A process of making purified extract of scutellaria barbata d. don
EP2222321A4 (en) * 2007-11-19 2013-02-13 Bionovo Inc THERAPY AGAINST CANCER WITH AN EXTRACT OF SCUTELLARIA BARBATA
US20090130118A1 (en) * 2007-11-19 2009-05-21 Bionovo, Inc. Scutellaria barbata extract and combinations for the treatment of cancer
CA2737137C (en) * 2007-12-05 2018-10-16 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
KR101169127B1 (ko) * 2008-01-15 2012-08-03 가톨릭대학교 산학협력단 비교유전자보합법을 이용한 간암 예후 진단방법 및진단키트
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
US8067178B2 (en) * 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
FR2929292A1 (fr) 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
KR20100132998A (ko) * 2008-04-04 2010-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 종양 성장, 혈관신생 및 전이를 차단하는 것을 목표로 하는 암에 대한 항체
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
US20090258942A1 (en) * 2008-04-14 2009-10-15 Bionovo, Inc. Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
EP2279416A4 (en) 2008-04-22 2011-08-24 Univ Washington METHOD FOR PREDICTING THE RISK OF METASTASES
EP2310024A4 (en) * 2008-05-06 2012-07-25 Bionovo Inc ESTROGENIC EXTRACTS FOR THE TREATMENT OF VAGINA AND VULVAATROPHY
US8093000B2 (en) 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
EP2294215B1 (en) * 2008-05-12 2013-01-16 Genomic Health, Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
JP2011523551A (ja) * 2008-05-15 2011-08-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血管形成の調節の新規ターゲット
CN101587125B (zh) * 2008-05-21 2013-07-24 林标扬 高表达癌症标记物和低表达组织器官标记物组合试剂盒
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
EP2294402A2 (en) * 2008-06-05 2011-03-16 Bionovo Inc. Method of quantification of multiple bioactives from botanical compositons
US20090312437A1 (en) * 2008-06-06 2009-12-17 Bionovo, Inc., A Delaware Corporation Anthraquinones and Analogs from Rhuem palmatum for Treatment of Estrogen Receptor Beta-Mediated Conditions
EP2469440A3 (en) * 2008-06-16 2014-01-01 Sividon Diagnostics GmbH Molecular markers for cancer prognosis
US20110158953A1 (en) * 2008-06-17 2011-06-30 University Of Rochester Tumor suppression through plexin c1
EP2322610B1 (en) 2008-07-16 2016-12-14 Medical and Biological Laboratories Co., Ltd. Anti-human clcp1 antibody and use thereof
EP2340027A4 (en) * 2008-09-03 2012-04-04 Bionovo Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CA3069082C (en) 2008-09-20 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8735082B2 (en) * 2008-11-10 2014-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
US8703920B2 (en) * 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
WO2010056662A1 (en) * 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2010056351A2 (en) * 2008-11-14 2010-05-20 Stc.Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
PT3130923T (pt) * 2008-11-14 2020-06-17 Brigham & Womens Hospital Inc Métodos terapêuticos relacionados com células estaminais
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
GB2512153B (en) * 2008-11-17 2014-11-12 Veracyte Inc Methods and compositions of molecular profiling for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
EP2391962B1 (en) * 2009-01-28 2016-12-21 University of Notre Dame du Lac Accelerated progression relapse test
WO2010086782A2 (en) * 2009-01-30 2010-08-05 Koninklijke Philips Electronics N.V. Methods for the subclassification of breast tumours
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
US20100303936A1 (en) * 2009-04-28 2010-12-02 Bionovo, Inc. A Delaware Corporation Method of reducing fat accumulation and inducing weight loss
EP2424987B1 (en) * 2009-05-01 2017-11-15 CuRNA, Inc. Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
WO2010127322A1 (en) * 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
ES2361808B8 (es) * 2009-05-25 2012-11-29 Consejo Superior De Investigaciones Cientificas (Csic) 20% Método de obtención de datos útiles para el diagnóstico o el pronóstico del cáncer colorrectal.
AU2010260152A1 (en) 2009-06-15 2012-02-02 Cardiodx, Inc. Determination of coronary artery disease risk.
CA2766152A1 (en) * 2009-06-24 2011-01-13 Lpath, Inc. Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid
EP2270510A1 (en) * 2009-07-02 2011-01-05 EMBL (European Molecular Biology Laboratory) Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
US20110039788A1 (en) * 2009-07-10 2011-02-17 University Of Miami Compositions, methods and kits for detecting and treating cancer
CA2770237A1 (en) * 2009-08-05 2011-02-10 Nexigen Gmbh Human hcv-interacting proteins and methods of use
WO2011028660A1 (en) * 2009-09-01 2011-03-10 Trustees Of Dartmouth College Compositions for inhibiting growth of cancer stem cells
US20120157342A1 (en) * 2009-09-02 2012-06-21 Shinji Mizuarai Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
JP5996429B2 (ja) * 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
WO2011030336A1 (en) * 2009-09-08 2011-03-17 Ramot At Tel-Aviv University Ltd. Methods of diagnosing amyotrophic lateral sclerosis (als)
US9588121B2 (en) 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
MX337650B (es) * 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.
US20110129822A1 (en) * 2009-12-01 2011-06-02 Precision Therapeutics, Inc. Multi drug response markers for breast cancer cells
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
JP6025567B2 (ja) * 2009-12-16 2016-11-16 カッパーアールエヌエー，インコーポレイテッド 膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療
GB0922085D0 (en) * 2009-12-17 2010-02-03 Cambridge Entpr Ltd Cancer diagnosis and treatment
EP2517555A4 (en) 2009-12-25 2014-09-24 Chugai Pharmaceutical Co Ltd SEARCHING AND SCREENING METHOD FOR A TARGET MOLECULE OF A CANCER WITH A NON-MENTAL ANIMAL MODEL WITH A NO-CANCER LINE OF TRANSPLANTED LINE
NZ600268A (en) 2010-01-11 2014-08-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
EP2415877A3 (en) * 2010-02-17 2012-02-15 Deutsches Krebsforschungszentrum Means and methods for diagnosing pancreatic cancer
WO2011106373A2 (en) * 2010-02-24 2011-09-01 University Of Maryland, Baltimore Arnt isoform 3 as a predictor of aminoflavone responsiveness in cancer cells
EP2845911B1 (en) 2010-03-31 2016-05-18 Sividon Diagnostics GmbH Method for breast cancer recurrence prediction under endocrine treatment
WO2011130495A1 (en) * 2010-04-14 2011-10-20 Nuvera Biosciences, Inc. Methods of evaluating response to cancer therapy
US12571798B2 (en) 2010-04-27 2026-03-10 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
WO2011140662A1 (en) * 2010-05-13 2011-11-17 The Royal Institution For The Advancement Of Learning / Mcgill University Cux1 signature for determination of cancer clinical outcome
IL243203A (en) 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
WO2012040614A1 (en) 2010-09-23 2012-03-29 The Washington University Compositions and methods for detecting cancer metastasis
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
JP2014509323A (ja) * 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ ドーパミン受容体遮断薬による癌の処置
MX353143B (es) 2011-02-28 2017-12-20 Genentech Inc Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
WO2012135845A1 (en) * 2011-04-01 2012-10-04 Qiagen Gene expression signature for wnt/b-catenin signaling pathway and use thereof
NZ713461A (en) 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
US20130064901A1 (en) * 2011-04-18 2013-03-14 Agency For Science, Technology And Research Gene expression profiling for classifying and treating gastric cancer
EP2702177B1 (en) * 2011-04-28 2017-04-12 New York University Genomic signatures of metastasis in prostate cancer
WO2012154567A2 (en) * 2011-05-06 2012-11-15 Albert Einstein College Of Medicine Of Yeshiva University Human invasion signature for prognosis of metastatic risk
US9791449B2 (en) 2011-06-03 2017-10-17 The General Hospital Corporation Ovarian cancer stem cells and methods of isolation and uses thereof
EP3281640A1 (en) 2011-06-17 2018-02-14 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
EP2723924A4 (en) * 2011-06-22 2015-03-25 Oncocyte Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
KR101360409B1 (ko) * 2011-07-11 2014-02-11 연세대학교 산학협력단 위암 암 줄기세포 특성에 기초한 위암의 치료용 타겟
US9873918B2 (en) 2011-08-11 2018-01-23 Albert Einstein College Of Medicine, Inc. Treatment of acute myeloid leukemia and myelodysplastic syndromes
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
CN103987861A (zh) 2011-10-14 2014-08-13 加州大学评议会 皮肤鳞状细胞癌和假性上皮瘤样增生的基于多重pcr的测试及其区分方法
EP2771488B1 (en) * 2011-10-24 2018-03-28 SignalChem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
WO2013071247A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene expression signatures of neoplasm responsiveness to theraphy
WO2013085482A1 (en) * 2011-12-05 2013-06-13 Phigenix, Inc. Compositions and methods for monitoring and detecting cancerous conditions
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
AU2012358810B2 (en) * 2011-12-23 2018-03-15 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
WO2013102118A2 (en) * 2011-12-30 2013-07-04 Anticancer, Inc. Imageable patient tumors in mice
KR20130081952A (ko) * 2012-01-10 2013-07-18 삼성전자주식회사 암 진단용 바이오마커 및 이를 이용한 암세포 분리 방법
WO2013109944A1 (en) * 2012-01-18 2013-07-25 The Trustees Of The University Of Pennsylvania Methods for assessing risk for cancer using biomarkers
WO2013116537A1 (en) * 2012-01-31 2013-08-08 Mount Sinai School Of Medicine A method to distinguish benign from malignant oncocytic cell tissue
DK3179393T3 (da) 2012-01-31 2020-07-27 Genomic Health Inc Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー／エス 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
CN104203977A (zh) 2012-02-15 2014-12-10 诺和诺德A/S（股份有限公司） 结合肽聚糖识别蛋白1的抗体
WO2013130791A1 (en) * 2012-02-29 2013-09-06 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
WO2013132354A2 (en) * 2012-03-06 2013-09-12 Oslo Universitetssykehus Hf Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer
EA201491692A1 (ru) * 2012-03-29 2015-06-30 Хелт Рисерч, Инк. КООПЕРИРОВАНИЕ p53 С МЕТИЛИРОВАНИЕМ ДНК И СУИЦИДАЛЬНЫМ ИНТЕРФЕРОНОВЫМ ОТВЕТОМ ДЛЯ КОНТРОЛЯ САЙЛЕНСИНГА ПОВТОРОВ И нкРНК
WO2013166373A1 (en) * 2012-05-03 2013-11-07 Zhong Wu Gene expression signature for il-6/stat3 signaling pathway and use thereof
TWI454698B (zh) * 2012-05-22 2014-10-01 Glory Biomedical Co Ltd 用於檢測腫瘤發生之腫瘤標誌、方法與套組
KR102320059B1 (ko) 2012-06-13 2021-11-01 아스트라제네카 아베 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
JP2012196226A (ja) * 2012-06-19 2012-10-18 Nippon Kayaku Co Ltd 癌幹細胞の培養方法、および癌幹細胞
CA2877721A1 (en) * 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
WO2014025582A1 (en) 2012-08-10 2014-02-13 Trustees Of Dartmouth College Method and kit for determining sensitivity to decitabine treatment
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
AU2013315128B2 (en) 2012-09-14 2019-01-03 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
WO2014062218A1 (en) * 2012-10-16 2014-04-24 University Of Southern California Colorectal cancer dna methylation markers
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
WO2014082067A1 (en) 2012-11-26 2014-05-30 The Johns Hopkins University Methods and compositions for diagnosing and treating gastric cancer
KR101467289B1 (ko) * 2013-01-22 2014-12-02 한국원자력의학원 Ｗｄｆｙ3를 측정하는 제제를 포함하는 방사선 저항성 또는 민감성 진단용 조성물 및 이의 용도
KR101469917B1 (ko) * 2013-01-22 2014-12-09 한국원자력의학원 Ｐｓａｐ를 측정하는 제제를 포함하는 방사선 저항성 또는 민감성 진단용 조성물 및 이의 용도
US20150376714A1 (en) 2013-02-01 2015-12-31 Sividon Diagnostics Gmbh Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
US20160010059A1 (en) * 2013-03-06 2016-01-14 The Regents Of The University Of California EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS BY HISTONE METHYLTRANSFERASE G9a INHIBITION
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP2796875B8 (en) * 2013-04-23 2020-11-25 Albert-Ludwigs-Universität Freiburg Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
CN104178562B (zh) * 2013-05-21 2018-11-09 生物梅里埃股份公司 一种大肠癌预后试剂盒
MX369911B (es) 2013-05-30 2019-11-26 Genomic Health Inc Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia.
AU2014284124B2 (en) 2013-06-20 2020-03-12 Immunexpress Pty Ltd Biomarker identification
ES2813877T3 (es) * 2013-08-28 2021-03-25 Crown Bioscience Inc Taicang Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
US10330682B2 (en) * 2013-10-31 2019-06-25 Sk Telecom Co., Ltd. Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using same
JP2017512304A (ja) 2014-02-06 2017-05-18 イミューンエクスプレス・プロプライエタリー・リミテッドＩｍｍｕｎｅＸｐｒｅｓｓ Ｐｔｙ Ｌｔｄ バイオマーカーシグネチャー法ならびにそのための装置およびキット
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
ES2913205T3 (es) * 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
EP3161489A4 (en) * 2014-06-26 2018-04-18 Institute for Systems Biology Markers and therapeutic indicators for glioblastoma multiforme (gbm)
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EA037844B1 (ru) 2014-07-17 2021-05-27 Ново Нордиск А/С Сайт-направленный мутагенез антител к trem-1
CN120518772A (zh) * 2014-07-17 2025-08-22 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
US10329323B2 (en) * 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
US10655185B2 (en) 2014-11-10 2020-05-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for diagnosis and prognosis of epithelial tumors
WO2016090323A1 (en) 2014-12-05 2016-06-09 Prelude, Inc. Dcis recurrence and invasive breast cancer
US10539566B2 (en) 2014-12-08 2020-01-21 Berg Llc Use of markers including filamin A in the diagnosis and treatment of prostate cancer
WO2016094802A1 (en) * 2014-12-11 2016-06-16 Worcester Polytechnic Institute Characterization of pre-cancer biomarker for prognostic screen
WO2017083682A1 (en) * 2015-11-12 2017-05-18 The Board Of Trustees Of Leland Stanford Junior University Labeled probe and methods of use
WO2017096458A1 (en) * 2015-12-07 2017-06-15 Ontario Institute For Cancer Research (Oicr) Immune gene signature predictive of anthracycline benefit
US11619632B2 (en) 2015-12-14 2023-04-04 Rowan University Early-stage Alzheimer's disease autoantibody biomarkers, target antigens and diagnostic uses thereof
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US10487365B2 (en) 2016-09-20 2019-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting expression of lnc-FANCI-2 in cervical cells
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
KR102014951B1 (ko) 2017-01-06 2019-08-27 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
US20200057075A1 (en) * 2017-02-20 2020-02-20 The Regents Of The University Of California Serologic assay for silent brain ischemia
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
JP2020514396A (ja) 2017-03-22 2020-05-21 ザ チルドレンズ メディカル センター コーポレーション Ｌｒｐ１結合剤およびその使用
AU2018240306A1 (en) * 2017-03-22 2019-10-10 Children's Medical Center Corporation PRSS2 inhibition
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019014663A1 (en) * 2017-07-14 2019-01-17 Dana-Farber Cancer Institute, Inc. MODULATION OF BIOMARKERS TO INCREASE ANTI-TUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF CANCER IMMUNOTHERAPY
WO2019014664A1 (en) * 2017-07-14 2019-01-17 Dana-Farber Cancer Institute, Inc. MODULATION OF BIOMARKERS TO INCREASE ANTITUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF ANTICANCER IMMUNOTHERAPY
US11345957B2 (en) 2017-07-18 2022-05-31 Exosome Diagnostics, Inc. Methods of treating glioblastoma in a subject informed by exosomal RNA signatures
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
US11773449B2 (en) 2017-09-01 2023-10-03 The Hospital For Sick Children Profiling and treatment of hypermutant cancer
CA3075265A1 (en) 2017-09-08 2019-03-14 Myriad Genetics, Inc. Method of using biomarkers and clinical variables for predicting chemotherapy benefit
KR102230314B1 (ko) * 2017-10-24 2021-03-22 주식회사 메드팩토 혈액으로부터 암을 진단하는 방법
KR102141997B1 (ko) 2017-11-22 2020-08-06 (주)인핸스드바이오 Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물
WO2019103456A2 (ko) * 2017-11-22 2019-05-31 울산대학교 산학협력단 Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물
CN112040970A (zh) 2017-11-29 2020-12-04 得克萨斯大学体系董事会 用于癌症疗法的组合物和方法
EP3754336B1 (en) * 2018-02-15 2024-01-17 3-D Matrix, Ltd. Cancer lesion tissue evaluation for optimizing effect of boron neutron capture therapy
WO2019195126A1 (en) 2018-04-02 2019-10-10 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
US20190381500A1 (en) * 2018-06-14 2019-12-19 Daisuke Takagi Cell contained container and cell contained container producing method, and cell chip
US20220187301A1 (en) 2018-09-14 2022-06-16 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
CN109321658B (zh) * 2018-11-23 2021-09-07 浙江大学 一种检测宫颈癌易感性的试剂盒
CN109628570A (zh) * 2018-12-07 2019-04-16 南方医科大学南方医院 一种检测TRIM29基因Tyr544Cys突变的试剂盒及其用途
CN109680005A (zh) * 2019-01-14 2019-04-26 广州市妇女儿童医疗中心 Wdr12基因在脑胶质瘤细胞的抑制和凋亡中的应用
CN110082529B (zh) * 2019-03-11 2022-04-19 南方医科大学深圳医院 一种肿瘤细胞表面标志物及其应用
CN110108878A (zh) * 2019-05-30 2019-08-09 四川大学华西医院 Eif2s1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN110412269A (zh) * 2019-06-26 2019-11-05 四川大学华西医院 Ndn自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
WO2021026335A1 (en) * 2019-08-08 2021-02-11 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
KR102055872B1 (ko) 2019-08-20 2019-12-13 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
US20240131204A1 (en) * 2019-10-10 2024-04-25 Cellectar Biosciences, Inc. Fractionated Dosing of a Phospholipid Ether Analog for the Treatment of Cancer
KR102168498B1 (ko) 2019-12-09 2020-10-21 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
CN111073979B (zh) * 2019-12-31 2021-08-17 上海交通大学 阻断ccl28趋化通路的胃癌治疗方法
CN111394334B (zh) * 2020-01-10 2022-02-15 中山大学 抑制ezh2活性的抗肿瘤多肽及其应用
US20230181686A1 (en) * 2020-05-27 2023-06-15 Baylor College Of Medicine Compositions and methods for treating neovascularization and ischemic retinopathies by targeting angiogenesis and cholesterol transport
CN113827727B (zh) * 2020-06-24 2025-04-29 上海交通大学医学院附属瑞金医院 Ptpn2抑制剂在kras突变肿瘤中的应用
JP7619556B2 (ja) * 2020-10-08 2025-01-22 藤倉化成株式会社 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー
KR102185037B1 (ko) 2020-10-14 2020-12-01 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
CN112522401B (zh) * 2020-11-16 2021-09-24 北京大学人民医院 Tox3基因过表达作为肝癌预后标志物中的应用
KR102205224B1 (ko) 2020-11-24 2021-01-20 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
TR202021768A1 (tr) * 2020-12-25 2022-07-21 Univ Istanbul Medipol Gli̇oma beyi̇n tümörünün hasta serumlarindan tespi̇ti̇ne yöneli̇k anti̇-slc3a2 otoanti̇korlarinin ve slc3a2?ni̇n kullanildiği yöntemler
KR102221671B1 (ko) 2021-01-13 2021-03-02 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
CN112980952B (zh) * 2021-02-05 2022-11-29 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于预测异柠檬酸脱氢酶1基因野生型胶质瘤预后与抗pd1治疗疗效的标志物及其应用
KR102243705B1 (ko) 2021-02-22 2021-04-23 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
KR102260250B1 (ko) 2021-02-22 2021-06-03 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
CN113063944B (zh) * 2021-03-05 2023-03-24 李朴 血清gsdme在b淋巴细胞白血病诊断、疗效监测及预后评估上的用途
WO2022216876A1 (en) * 2021-04-08 2022-10-13 City Of Hope Cancer treatment by targeting proteins or interactions of ephrinb-rgs3-kif20a-sept7 axis
CN113278057B (zh) * 2021-04-23 2023-05-26 中国人民解放军海军军医大学 一种维甲酸诱导蛋白16特异性多克隆抗体的制备和应用
CN120392997A (zh) 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
EP4374172A4 (en) * 2021-07-21 2025-05-14 Mercy Bioanalytics, Inc. COMPOSITIONS AND METHODS FOR DETECTING BREAST CANCER
CN113916754B (zh) * 2021-10-12 2023-11-10 四川大学华西医院 用于检测乳腺癌患者循环肿瘤细胞的细胞表面标志物及应用
CN114350799A (zh) * 2021-12-28 2022-04-15 深圳市人民医院 Htr2c在低级别胶质瘤的预后中的应用
CN115786501B (zh) * 2022-07-02 2023-06-16 武汉大学 一种与结直肠癌早期筛查和辅助诊断相关的增强子功能位点及其应用
CN115976203B (zh) * 2022-08-25 2023-08-01 威海市立医院 Hap1在制备诊断、预防和/或治疗胃癌的产品中的应用
CN120322559A (zh) * 2022-10-18 2025-07-15 株式会社Nb健康研究所 抗体、核酸、细胞和药物
CN115873798A (zh) * 2022-11-15 2023-03-31 重庆医科大学附属儿童医院 一种抗CD24 scFv靶向修饰的类外泌体的新型药物载体的制备方法
CN117192122B (zh) * 2023-10-08 2025-02-11 山东大学齐鲁医院 一种预测肝内胆管癌预后及培美替尼治疗效果的生物标志物及其应用
CN117343932B (zh) * 2023-12-06 2024-03-22 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 靶向抑制MS4A7基因表达的siRNA及其应用
CN117487923B (zh) * 2023-12-27 2024-05-31 湖南家辉生物技术有限公司 Habp2基因突变体作为检测靶点的应用、具有其的检测试剂和/或检测试剂盒
CN120044256A (zh) * 2025-02-11 2025-05-27 中国人民解放军总医院第七医学中心 载脂蛋白apod缺失作为诊断宫颈癌分子标志物的应用
CN119916024B (zh) * 2025-04-02 2025-06-17 浙江大学 Smurf2蛋白或其编码基因作为靶点在制备抗肿瘤药物中的应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4109496A (en) * 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) * 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4411990A (en) * 1979-06-13 1983-10-25 University Patents, Inc. Primary bioassay of human tumor stem cells
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5087570A (en) * 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US4981785A (en) * 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US4968103A (en) * 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5994617A (en) * 1988-09-19 1999-11-30 Hsc Research Development Corporation Engraftment of immune-deficient mice with human cells
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
IL101728A (en) * 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5856441A (en) * 1991-05-03 1999-01-05 Yale University Serrate fragments and derivatives
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) * 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6353150B1 (en) * 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
US6004924A (en) * 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
US5869282A (en) * 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
EP0552108B1 (en) * 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5376313A (en) * 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5672499A (en) * 1992-07-27 1997-09-30 California Institute Of Technology Immoralized neural crest stem cells and methods of making
US5654183A (en) * 1992-07-27 1997-08-05 California Institute Of Technology Genetically engineered mammalian neural crest stem cells
NZ256154A (en) * 1992-07-27 1997-02-24 California Inst Of Techn Production of mammalian multipotent neural stem cells, antibodies
US5589376A (en) * 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5849553A (en) * 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
KR100283601B1 (ko) * 1993-02-19 2001-03-02 아만 히데아키 글리세롤 유도체, 디바이스 및 의약 조성물
US5876978A (en) * 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) * 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5639606A (en) * 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
ATE336587T1 (de) * 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US5650317A (en) * 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5821108A (en) * 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US6019978A (en) * 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
CA2239957A1 (en) * 1995-12-22 1997-07-03 Abbott Laboratories Fluorescence polarization immunoassay diagnostic method
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US5885529A (en) * 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
US5935792A (en) * 1996-08-29 1999-08-10 The Regents Of The University Of California KUZ, a novel family of metalloproteases
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
DE69837839T2 (de) * 1997-03-07 2007-12-13 Clare Chemical Research LLC, Denver Fluorometrischer Nachweis mit sichtbarem Light
US6080912A (en) * 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
US5830730A (en) * 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
US6379925B1 (en) * 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6136952A (en) * 1997-06-25 2000-10-24 University Of Washington Human jagged polypeptide, encoding nucleic acids and methods of use
NZ500657A (en) 1997-07-11 2002-11-26 Introgene B Interleukin-3 gene therapy for cancer
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6197523B1 (en) * 1997-11-24 2001-03-06 Robert A. Levine Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
CA2340682A1 (en) 1998-08-14 2000-02-24 Aventis Pharmaceuticals Products Inc. Adenovirus formulations for gene therapy
CN1257286C (zh) 1998-08-27 2006-05-24 森泰莱昂公司 用于递送异源基因的定向腺病毒载体
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
US6380362B1 (en) * 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
US6632620B1 (en) * 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20020151487A1 (en) * 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
US20020061289A1 (en) * 2000-10-04 2002-05-23 Boman Bruce M. Stem cell-based methods for preventing and treating tumor
ATE371018T1 (de) * 2001-06-22 2007-09-15 Stemcells Inc Le-zellen (liver engrafting cells), assays und verwendungen davon
AU2002364537A1 (en) * 2001-12-07 2003-06-23 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
US20050089896A1 (en) * 2003-02-18 2005-04-28 Roy Frans V. Method to control tumor progression and invasiveness
US20060134622A1 (en) * 2002-12-20 2006-06-22 Meena Augustus Amplified cancer target genes useful in diagnosis and thereapeutic screening
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
CN109837342A (zh) * 2017-11-28 2019-06-04 立森印迹诊断技术（无锡）有限公司 一种用于检测乳腺肿瘤良恶性程度的分级模型及其应用
CN113633778A (zh) * 2021-10-18 2021-11-12 广州医科大学附属肿瘤医院 Bex2在制备热化疗耐药胃癌增敏药物或制备预测疗效产品的应用
CN113633778B (zh) * 2021-10-18 2022-01-07 广州医科大学附属肿瘤医院 Bex2在制备热化疗耐药胃癌增敏药物或制备预测疗效产品的应用
CN114940714A (zh) * 2022-05-20 2022-08-26 湖南师范大学 肝癌标志物soat1单克隆抗体制备及其应用
CN114940714B (zh) * 2022-05-20 2023-06-16 湖南师范大学 肝癌标志物soat1单克隆抗体制备及其应用

Also Published As

Publication number Publication date
US20100093556A1 (en) 2010-04-15
EP1907858A4 (en) 2009-04-08
WO2006138275A2 (en) 2006-12-28
US20110183866A1 (en) 2011-07-28
AU2006259583A1 (en) 2006-12-28
EP1907858A2 (en) 2008-04-09
US7939263B2 (en) 2011-05-10
WO2006138275A3 (en) 2007-11-15
JP2008546387A (ja) 2008-12-25
US20070105133A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
US7939263B2 (en) Compositions and methods for treating and diagnosing cancer
EP2481814A2 (en) Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) Compositions and methods for treating and diagnosing cancer
CN1852974A (zh) 用于治疗和诊断癌症的组合物和方法
US12421557B2 (en) Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US12105089B2 (en) Cell atlas of the healthy and ulcerative colitis human colon
US12227578B2 (en) Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
US20230203485A1 (en) Methods for modulating mhc-i expression and immunotherapy uses thereof
AU2012203564A1 (en) Compositions and methods for treating and diagnosing cancer
AU2010326066A1 (en) Classification of cancers
WO2019079647A2 (en) IA STATISTICS FOR DEEP LEARNING AND PROBABILISTIC PROGRAMMING, ADVANCED, IN BIOSCIENCES
US11709164B2 (en) Approach for universal monitoring of minimal residual disease in acute myeloid leukemia
US20170037480A1 (en) Hsf1 in tumor stroma
US12584844B2 (en) Flow cytometry immunoprofiling of peripheral blood
US20250034651A1 (en) Systems and methods for characterizing and treating breast cancer
US20240428948A1 (en) Unsupervised Machine Learning Methods
WO2024003360A1 (en) Biomarkers and uses thereof for the treatment of neuroblastoma
US20240115699A1 (en) Use of cancer cell expression of cadherin 12 and cadherin 18 to treat muscle invasive and metastatic bladder cancers
US20100055686A1 (en) Methods for diagnosis of pediatric common acute lymphoblastic leukemia by determining the level of gene expression
Voth Park Exploiting Multi-Cell Type Cultures to Elucidate Tumor Cell Features That Impact Macrophage Phenotype
Foley Investigation of Racial Differences in Uterine Serous Carcinoma Reveals Distinct Tumor Immune Signaling
Class et al. Patent application title: MARKERS FOR MATURE BETA-CELLS AND METHODS OF USING THE SAME Inventors: Douglas A. Melton (Lexington, MA, US) Douglas A. Melton (Lexington, MA, US) Sinisa Hrvatin (Cambridge, MA, US)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued